IMPROVE 2022 International Meeting on Pathway-Related Obesity: Vision of Excellence.

Autor: Kühnen P; Department of Pediatric Endocrinology and Diabetology, Charité Universitätsmedizin Berlin, Berlin, Germany., Argente J; Departments of Pediatrics & Pediatric Endocrinology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain., Clément K; Assistance Publique-Hôpitaux de Paris, Nutrition Department, Pitié-Salpêtrière Hospital, Paris, France.; INSERM, Nutrition and Obesity: Systemic Approaches, NutriOmics, Research Unit, Sorbonne Université, Paris, France., Dollfus H; CARGO and Department of Medical Genetics, University of Strasbourg, Strasbourg, France., Dubern B; INSERM, Nutrition and Obesity: Systemic Approaches, NutriOmics, Research Unit, Sorbonne Université, Paris, France.; Sorbonne Université, Trousseau Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France., Farooqi S; Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK., de Groot C; Sophia Children's Hospital, Erasmus Medical Center, Rotterdam, The Netherlands., Grüters A; Department of Pediatric Endocrinology and Diabetes, Charité Universitätsmedizin Berlin, Berlin, Germany., Holm JC; The Children's Obesity Clinic, accredited European Centre for Obesity Management, Department of Pediatrics, Copenhagen University Hospital Holbæk, Copenhagen, Denmark., Hopkins M; School of Food Science and Nutrition, University of Leeds, Leeds, UK., Kleinendorst L; Department of Clinical Genetics, Amsterdam UMC, Amsterdam, The Netherlands., Körner A; Center for Pediatric Research, Department of Pediatrics, LIFE Research Center for Civilization Diseases, University Hospital Leipzig, Leipzig, Germany., Meeker D; Rhythm Pharmaceuticals, Boston, Massachusetts, USA., Rydén M; Department of Medicine H7, Karolinska Institute, Stockholm, Sweden.; Department of Endocrinology and Metabolism, Karolinska University Hospital, Stockholm, Sweden., von Schnurbein J; Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany., Tschöp M; Institute for Diabetes and Obesity, Helmholtz Zentrum, Munich, Germany., Yeo GSH; Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK., Zorn S; Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany., Wabitsch M; Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany.
Jazyk: angličtina
Zdroj: Clinical obesity [Clin Obes] 2024 Jun; Vol. 14 (3), pp. e12659. Date of Electronic Publication: 2024 Apr 11.
DOI: 10.1111/cob.12659
Abstrakt: Nearly 90 clinicians and researchers from around the world attended the first IMPROVE 2022 International Meeting on Pathway-Related Obesity. Delegates attended in person or online from across Europe, Argentina and Israel to hear the latest scientific and clinical developments in hyperphagia and severe, early-onset obesity, and set out a vision of excellence for the future for improving the diagnosis, treatment, and care of patients with melanocortin-4 receptor (MC4R) pathway-related obesity. The meeting co-chair Peter Kühnen, Charité Universitätsmedizin Berlin, Germany, indicated that change was needed with the rapidly increasing prevalence of obesity and the associated complications to improve the understanding of the underlying mechanisms and acknowledge that monogenic forms of obesity can play an important role, providing insights that can be applied to a wider group of patients with obesity. World-leading experts presented the latest research and led discussions on the underlying science of obesity, diagnosis (including clinical and genetic approaches such as the role of defective MC4R signalling), and emerging clinical data and research with targeted pharmacological approaches. The aim of the meeting was to agree on the questions that needed to be addressed in future research and to ensure that optimised diagnostic work-up was used with new genetic testing tools becoming available. This should aid the planning of new evidence-based treatment strategies for the future, as explained by co-chair Martin Wabitsch, Ulm University Medical Center, Germany.
(© 2024 The Authors. Clinical Obesity published by John Wiley & Sons Ltd on behalf of World Obesity Federation.)
Databáze: MEDLINE
Externí odkaz: